Bruker Corporation Bruker Corporation

Bruker Corporation

BRKR

Rang in Aktien #2331
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Aktienkurs
$55.38
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$8.44B
Veränderung (1 Tag)
1.05%
Veränderung (1 Jahr)
45.30%
Land
US
Handel Bruker Corporation (BRKR)

Kategorie

Healthcare
Gewinn für Bruker Corporation (BRKR)
Gewinn im Jun 2026 TTM: $-28.10M
Laut den aktuellen Finanzberichten von Bruker Corporation betragen die aktuellen Gewinne des Unternehmens $-28.10M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $205.20M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $546.20M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Bruker Corporation von 2000 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-28.10M -195.90%
2025 $29.30M -85.72%
2024 $205.20M -62.43%
2023 $546.20M 31.65%
2022 $414.90M 5.41%
2021 $393.60M 74.31%
2020 $225.80M -19.47%
2019 $280.40M 14.59%
2018 $244.70M 23.71%
2017 $197.80M 11.37%
2016 $177.60M 38.75%
2015 $128.00M 26.36%
2014 $101.30M -18.70%
2013 $124.60M -9.91%
2012 $138.30M -4.95%
2011 $145.50M -3.06%
2010 $150.10M 16.27%
2009 $129.10M 38.52%
2008 $93.20M 91.72%
2007 $48.61M 41.23%
2006 $34.42M 188.06%
2005 $11.95M -344.01%
2004 $-4.90M -37.46%
2003 $-7.83M 89.27%
2002 $-4.14M -168.88%
2001 $6.01M 158.88%
2000 $2.32M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$7.51B -26,829.54%
US
$5.56B -19,897.15%
IE
$5.15B -18,420.28%
US
$3.86B -13,840.21%
US
- -
DE